XLO Q4 2022 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$28M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$23M

Net Income

-$22M

EPS (Diluted)

$-0.79

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$19M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$139M

Total Liabilities

$34M

Stockholders' Equity

$106M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$23M	-$20M	-18.5%
Net Income	-$22M	-$20M	-14.0%